DexCom, Inc.
Here’s whether DexCom, Inc. (DXCM) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+4.11% over 10 days); RSI 48 — healthy momentum range; 3-month momentum positive (+16.2%). Concerns: below the 50-day MA (medium-term momentum negative); weak 1-year return of -17.5%. Currently 20.5% off its 52-week high. Score: +3/7.
DXCM is holding above its long-term 200-day MA ($67.50) but has slipped below the 50-day MA ($71.71), pointing to short-term weakness in an otherwise intact trend. An RSI of 48.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -17.5% compares to +16.5% for SPY (trailed the market by 34.0%). The current 20.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.